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Hypoxia-associated markers are involved in the progression of several malignancies, but are relatively unstudied in Barrett’s
carcinogenesis. Our aim was to assess the immunohistochemical expression of hypoxia-inducible factor (HIF)-1a, HIF-2a,
erythropoietin (Epo), Epo receptor (Epo-R), Glut-1 and vascular endothelial growth factor (VEGF) along with Ki67/MIB-1 in the
Barrett’s metaplasia–dysplasia–adenocarcinoma sequence. Endoscopic biopsies of normal squamous epithelium (NSE) (n¼20),
columnar-lined oesophagus (CLO) (n¼15), CLO with intestinal metaplasia (n¼20), dysplasia (n¼17) and Barrett’s type
adenocarcinoma (n¼20) were obtained. Immunohistochemistry was performed on the paraffin-embedded tissue. A score was
calculated for each marker (range 0 300) by multiplying intensity (none 0, weak 1, moderate 2, strong 3) by percentage of
expression (range 0–100). Significant increases in the expression of HIF-2a (P¼0.014), VEGF (Po0.0001), Epo-R (Po0.0001) and
Ki67 (Po0.0001) were found as tissue progressed from NSE to adenocarcinoma. HIF-2a was expressed late in the sequence and was
only seen in dysplasia and adenocarcinoma. High HIF-2a expression was seen in 12 out of 20 Barrett’s type adenocarcinoma. The late
expression of HIF-2a in the Barrett’s carcinogenesis sequence and its high expression in adenocarcinoma suggest that it is worth
further investigation as a marker of disease progression and therapeutic target.
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Barrett’s oesophagus is a pre-malignant condition associated with
a3 0  125-fold increase in the risk of developing adenocarcinoma
compared with unaffected individuals (Guindi and Riddell, 2003).
The normal squamous oesophageal lining is transformed via injury
caused by gastro-oesophageal reflux disease into columnar-lined
epithelium. The subsequent development of specialised intestinal
metaplasia (IM) is a key risk factor for tumorigenesis (Spechler
and Goyal, 1996). Additional genetic and epigenetic events are
associated with further progression through increasingly severe
degrees of dysplasia to adenocarcinoma. This process is termed
the Barrett’s metaplasia–dysplasia–adenocarcinoma sequence
(Jankowski et al, 1999). Oesophageal adenocarcinoma is a devastating
disease, which is increasing in incidence. In Europe, only about a
quarter of all oesophageal cancers are operable and, for these,
5-year survival is around 20 30% (Keighley, 2003). Regular
endoscopic surveillance is recommended for patients with Barrett’s
metaplasia because of their elevated risk of developing adeno-
carcinoma (Bergman and Tytgat, 2005). Cancers detected in such
programmes are frequently early stage and have a better prognosis
(Streitz et al, 1993; Corley et al, 2002). However, these analyses are
subject to confounding factors such as lead and length time bias,
and it remains to be established conclusively if surveillance is
beneficial.
The exact molecular mechanisms of Barrett’s adenocarcinoma
development remain largely unknown, but there is interest in
investigating molecular biomarkers for predicting patient risk of
disease progression (Bergman and Tytgat, 2005). The rationale
underlying such work is to find approaches for identifying high-
risk patients who would be targeted for surveillance endoscopy
(Preston and Jankowski, 2006). Although many potential biomar-
kers have been assessed, none is currently in routine clinical use
(McManus et al, 2004).
Hypoxia is implicated in the progression of several malignan-
cies, but is relatively unstudied in the Barrett’s carcinogenic
sequence. Tumour hypoxia is a key factor driving the development
of malignancy, and the master regulatory protein that controls the
response of cells to changing oxygen levels is hypoxia-inducible
factor-1 (HIF-1). HIF-1 consists of constitutively expressed HIF-1b
complexed with one of three subunits (HIF-1a, HIF-2a or HIF-3a).
In hypoxia, HIF-1 upregulates genes involved in a variety of
cellular processes that include glucose metabolism, erythropoiesis,
cell proliferation, angiogenesis and apoptosis. Studies have shown
progressively increased HIF-1a expression in breast (Bos et al,
2001), skin (Costa et al, 2001), gastric (Griffiths et al, 2007) and
cervical (Acs et al, 2003) cancer development. Hypoxia-inducible
factor-1a is a key mediator of angiogenesis via activation of
vascular endothelial growth factor (VEGF) (Forsythe et al, 1996),
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swhich is associated with oesophageal carcinogenesis (Couvelard
et al, 2000; Auvinen et al, 2002; Lord et al, 2003; Mobius et al,
2003). Hypoxia-inducible erythropoietin (Epo) regulates erythro-
poiesis by stimulating the growth and differentiation of red blood
cell precursors (Yasuda et al, 2003). Erythropoietin and erythro-
poietin receptor (Epo-R) are expressed in a number of cancers and
are involved in breast (Acs et al, 2002), endometrial (Acs et al,
2004), melanoma (Kumar et al, 2005) and prostate (Feldman et al,
2006) tumorigenesis. The following study was established to
investigate the hypothesis that hypoxia plays a role in the aetiology
of oesophageal cancer. The specific goals of the research were to
determine whether the expression of hypoxia-associated proteins
increases along the Barrett’s carcinogenic sequence and to
highlight potential markers of interest for further study as
predictors of disease progression in patients with Barrett’s
dysplasia. Four hypoxia-associated markers were selected that
have not been assessed in the Barrett’s sequence: HIF-1a, HIF-2a,
Epo, Epo-R. Although studied previously, VEGF and Glut-1 were
studied also. The widely investigated Ki67 was included as a
comparator. The expression of the proteins was assessed using
immunohistochemistry in paraffin-embedded material representing
the Barrett’s metaplasia–dysplasia–adenocarcinoma sequence.
METHODS
Endoscopic biopsies
The study was approved by the South Manchester Ethics
Committee. Paraffin-embedded endoscopic biopsies of 20 normal
squamous epithelium (NSE), 15 columnar-lined oesophagus
(CLO), 20 CLO with IM, 17 dysplasia and 20 Barrett’s type
adenocarcinoma were obtained from the pathology archive of
South Manchester University Hospitals NHS Trust. Histopathology
and endoscopy reports were reviewed to confirm biopsy location
in the oesophagus.
Haematoxylin and eosin slides were reassessed by a consultant
upper gastrointestinal pathologist (SAP) to select the most suitable
specimens for immunohistochemistry. Biopsy samples were
classified using internationally agreed criteria (Ibrahim, 2000;
Schlemper et al, 2000; Odze, 2006). NSE was defined as normal
squamous epithelium with no evidence of adjacent CLO or IM.
Seventeen of the biopsies designated NSE had additional fragments
of adjacent normal gastric cardia mucosa (NCM) used as
additional controls to explore changes due to metaplastic
transformation. CLO was defined as the presence of columnar
metaplasia of the lower oesophagus without evidence of IM. CLO
with IM was defined as columnar metaplasia of the lower
oesophagus associated with specialised IM (characterised by
goblet cells). Dysplasia was defined as unequivocal neoplastic
epithelium strictly confined within the basement membrane of the
gland from which it arises. This was classified as low (n¼10) and
high (n¼7) grade depending on the degree of abnormality
present. Adenocarcinoma was defined as invasive malignancy of
adenocarcinoma cell type arising from the lower oesophagus in
association with CLO.
Immunohistochemistry
As deterioration can occur in stored sections (Bertheau et al, 1998;
Olapade-Olaopa et al, 2001), staining was carried out within 3
months of cutting. Sections (4mm) were dewaxed in xylene and
rehydrated using a series of ethanol solutions of increasing
dilution.
HIF-1a immunohistochemistry
Sections were microwaved for 25min in 10mM sodium citrate
buffer solution (pH 6.0) and endogenous peroxidase quenched
with 0.03% hydrogen peroxide in methanol. HIF-1a was detected
using the Tyramide Signal Amplification System (PerkinElmer Life
Sciences, NEL 700A001KT Beaconsfield, UK), which is based on
streptavidin–biotin–horseradish peroxidase complex formation.
Following the blocking step described in the manufacturer’s
protocol, the primary antibody was applied (Table 1). Biotinylated
rabbit anti-mouse (DakoCytomation, E0413, Ely, UK) diluted
1:400 was used as the secondary antibody and the sections were
incubated for 30min at room temperature. Additional blocking
precautions were employed at this stage in order to minimise the
amplification of nonspecific background (Kim et al, 2003). The
antibody was visualised using diaminobenzidine (DakoCytomation,
UK) and sections counterstained with haematoxylin, dehydrated
and mounted.
HIF-2a, Epo, Epo-R, VEGF, Glut-1 and Ki67
immunohistochemistry
Antigen retrieval was carried out where necessary by microwaving
for 25min in either 10mM sodium citrate (pH 6.0) or 0.05M
Tris-HCl/1mM EDTA (pH 8.5 or 9.0) buffer solution (Table 1).
After quenching endogenous peroxidase, nonspecific binding was
blocked using 10% casein (Vector Laboratories, SP-5020, Peterbor-
ough, UK). The primary antibody was applied and the sections were
incubated as described (Table 1). Mouse or rabbit (EnVisionPlus
System; DakoCytomation, UK) secondary antibodies were used to
detect the antigen using a 30-min incubation at room temperature.
Following visualisation with diaminobenzidine, sections were
counterstained with haematoxylin, dehydrated and mounted. In
each case, substitution of the primary antibody with an identical
concentration of immunoglobulins (IgG1; DakoCytomation, UK)
from the same species served as a negative control. Positive and
negative (or low) tissue controls from gastric, cervical or head and
neck cancer with known staining characteristics were used in each
batch. Batch-to-batch variation was assessed by choosing two
sections showing high and low protein expression and running
additional sections from these biopsies with each batch.
Table 1 Summary of the immunohistochemical methods used, number of biopsies examined and overall percentiles for each immunohistochemical
marker studied
Antigen Isotype Source Ref Conc. (lg/ml
 1) Incubation pH
a n IHC Score
b
HIF-1a Mouse IgG1 BD Biosciences 610958 2.5 o/n 41C 6.0 90
c 1.3 (0,10)
HIF-2a Mouse IgG1 Cancer Research UK E190b 6 o/n 41C 6.0 89
c 0 (0,0.5)
VEGF Rabbit polyclonal Santa Cruz Biotechnology A-20 2 1h 251C 8.5 89
c 80 (30, 192)
EPO Mouse IgG1 R&D Systems 9C21D11 30 o/n 41C 6.0 88
c 7.5 (0,125)
EPO/R Rabbit polyclonal Santa Cruz Biotechnology C-20 0.4 o/n 41C 6.0 88
c 160 (30,270)
Glut-1 Rabbit polyclonal Alpha Diagnostics Int GT 12-A 10 1h 371C n/a 89
c 0 (0,5)
Ki-67 Mouse IgG1 Dako-Cytomation MIB-1 0.8 o/n 41C 9.0 89
c 30 (15,154)
IHC¼immunohistochemistry; o/n¼overnight; n/a¼not applicable; conc¼concentration.
aAntigen retrieval pH.
bImmunohistochemical score was calculated from percentage
(0–100) multiplied by intensity (0–3) of expression for each marker studied – 50th percentile (25 and 75th percentiles).
cInsufficient tissue available for scoring in some biopsies.
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A score was calculated for each marker (range 0–300) by
multiplying intensity (none 0, weak 1, moderate 2, strong 3) by
percentage of expression (range 0–100). Scoring was performed
blind by two independent pathologists (SAP, SMG). Any disagree-
ment was resolved by discussion to obtain a final score.
Statistics
Spearman’s rank non-parametric test was used to calculate
interobserver and intermarker correlations. To assess possible
differences in expression levels in the carcinogenesis sequence, the
rank–sum tests Mann–Whitney (for comparison between two
groups) and Kruskal–Wallis (for comparison between all biopsy
groups) were applied. The non-parametric Jonckheere—Terpstra
(JT) test was also used to identify ordered differences among the
biopsy categories in the oesophageal carcinogenesis sequence.
With this test, the null hypothesis is that the distribution does not
differ across ordered categories. To test marker progression in the
Barrett’s carcinogenesis sequence, the categories NSE, CLO, IM,
Dys and Adeno were used. All statistical tests were two-sided at
the 0.05 significance level. As adjusting statistical significance
depending on the number of tests performed can create problems
(Perneger, 1998), no allowance was made for multiple testing.
RESULTS
The 92 specimens were from 64 men and 29 women who had a
median age of 64 (range 26–87) years. There was insufficient tissue
left for scoring of between two and four sections for each marker
(Table 1). Interobserver agreement for all the markers studied was
highly statistically significantly correlated (Po0.0001 for all). The
final consensus scores in terms of percentiles for each marker are
shown in Table 1. There were weak, statistically significant
correlations between the expression levels of a number of markers:
Ki67 expression correlated with that of HIF-2a (r¼0.38,
Po0.001), VEGF (r¼0.66, Po0.001) and Epo-R (r¼0.67,
Po0.001); Glut-1 expression correlated with that of HIF-1a
(r¼0.38, Po0.001), HIF-2a (r¼0.38, P¼0.003) and Epo
(r¼0.62, Po0.001); HIF-2a expression correlated with that of
HIF-1a (r¼0.40, Po0.001) and VEGF (r¼0.30, P¼0.004); Epo-R
expression correlated with that of VEGF (r¼0.71, Po0.001) and
inversely with that of Epo (r¼ 0.28, P¼0.009).
Descriptive pathology
Photomicrographs of the immunohistochemical expression of each
marker studied are shown in Figure 1. Hypoxia-inducible factor-1a
staining was predominantly nuclear, and occasional cytoplasmic
staining was not scored. Staining was focal and tended to be
intense in areas adjacent to inflammation and ulceration. Similarly,
HIF-2a staining was predominantly nuclear and occasional focal
cytoplasmic staining was ignored. Hypoxia-inducible factor-2a was
not seen in either CLO or IM, but its expression tended to be high
(450% positive cells) in dysplasia and carcinoma. No particular
preferred location of staining was identified.
VEGF was expressed in the cytoplasm. Where squamous
epithelium was seen there was staining of the basal layers. In
CLO and IM, staining was seen in mucous cells (fovelar-type), on
the surface, in all layers of the foveolar pit and in goblet cells.
In dysplasia and carcinoma, staining was random with no specific
architectural pattern identified.
Erythropoietin expression was granular and cytoplasmic.
Staining in CLO and IM was mainly in mucous cells located in



















Figure 1 Representative photomicrographs of HIF-1a, HIF-2a, Epo and Epo-R in Barrett’s metaplasia–dysplasia–adenocarcinoma sequence.
NSE¼normal squamous epithelium; CLO¼columnar-lined oesophagus; IM, intestinal metaplasia; Dys¼dysplasia; Adeno¼adenocarcinoma.
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sMucous cells in all locations stained (surface and all levels of the
foveolar pit) but with a tendency for a higher percentage of surface
cells to be positive. Focal staining of chief and parietal cells was
also identified. Dysplasia and carcinoma had a random staining
pattern. Epo-R staining was cytoplasmic with an increase in
intensity around the nucleus. Lymphocytes within the lamina
propria were positive for the antibody and acted as an internal
control. In CLO and IM, staining was seen in mucous-secreting
cells predominantly of the neck region of the foveolar pits. In these
cells, the cytoplasmic staining was mainly towards the basal region
of the cell around the basally placed nucleus. Staining of goblet
cells was also present. In Dys and Adeno, staining was diffuse with
a random location of positive cells.
Glut-1 was expressed in lymphocytes within the lamina propria,
which acted as an internal control. Staining was cytoplasmic with
only a few positive cases detected. No specific location of staining
was identified.
Ki67 staining was nuclear. In CLO and IM, mucous cells of the
deep and middle third of the foveolar pit showed positive staining
with the surface region being negative. Positive staining was also
seen in the glands deep to the foveolar pits. In dysplasia and
carcinoma, staining was increased and present in all layers of the
mucosa with loss of the normal proliferation pattern.
In some biopsies, specialised gastric body mucosa containing
chief and parietal cells was present (17 NSE, 8 CLO, 3 IM, 1
dysplasia and 2 adenocarcinoma). The parietal and chief cells all
showed strong staining for Epo, Epo-R and VEGF immunohis-
tochemistry, regardless of the morphology of adjacent mucosa.
This staining was not observed with HIF-1a,H I F - 2 a, Glut-1 and Ki67















































































NCM NSE CLO IM Dys Adeno
Figure 2 Box and whisker plots of each immunohistochemical marker in the Barrett’s sequence. The box represents the 25–75 quartile with a median
line. The whiskers extend to minimum and maximum values, but exclude outlying and far out values. Individual data points are also shown. NSE¼normal
squamous epithelium; NCM¼normal gastric cardia mucosa; CLO¼columnar-lined oesophagus; IM¼intestinal metaplasia; Dys¼dysplasia;
Adeno¼adenocarcinoma.
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sor true positive staining. Data from these areas were therefore not
included in the calculated score for each biopsy.
Marker expression along the Barrett’s metaplasia–
dysplasia–adenocarcinoma sequence
Box and whisker plots of marker expression are shown in Figure 2.
Using Kruskall–Wallis testing, all markers showed significant
differences in expression in the Barrett’s metaplasia–dysplasia–
adenocarcinoma sequence (Po0.001 for all). The JT test assesses
ordered differences and showed significant increases in expression
for HIF-2a (P¼0.014), VEGF (Po0.0001), Epo-R (Po0.0001) and
Ki67 (Po0.0001) from normal squamous tissue to adenocarcinoma.
Erythropoietin, Glut-1 and HIF-1a showed a decrease in expres-
sion from NSE to CLO (Po0.001 for all). There were significant
differences in marker expression in adenocarcinoma compared
with dysplasia for HIF-1a (P¼0.014), HIF-2a (P¼0.012), Ki67
(P¼0.0001) and Epo-R (P¼0.042).
In some samples of CLO (n¼8), IM (n¼10), dysplasia (n¼6)
and adenocarcinoma (n¼16), adjacent NSE was available for
direct comparison. Increases in the expression of HIF-2a, VEGF,
Ki67 and Epo-R in the relevant biopsy category compared with
adjacent NSE are shown (Figure 3).
DISCUSSION
Significant increases in the expression of HIF-2a, VEGF, Epo-R
and Ki67 (Po0.0001) were found along the Barrett’s metaplasia–
dysplasia–adenocarcinoma sequence. Previous studies have
shown the importance of Ki67 expression and proliferation in
the progression of Barrett’s oesophagus (Iftikhar et al, 1992; Reid
et al, 1993; Polkowski et al, 1995; Feith et al, 2004). Similarly, the
role of VEGF and angiogenesis in the Barrett’s sequence has been
widely reported and discussed (Couvelard et al, 2000; Auvinen
et al, 2002; Lord et al, 2003; Mobius et al, 2003).
Our finding that Glut-1 is expressed in adenocarcinoma but not
in dysplasia agrees with published work (Younes et al, 1997, 2000).
These papers reported higher (45–69%) expression of Glut-1 in
Barrett’s adenocarcinoma than the 25% found here. As there was
no expression in high-grade dysplasia, the authors concluded that
‘Glut-1 immunostaining may provide a unique marker that could
distinguish between high grade dysplasia and a well-differentiated
carcinoma, when such distinction cannot be made on purely
morphological grounds’ (Younes et al, 1997). Our confirmatory
observation adds weight to this conclusion. We also found a low
percentage of Glut-1 staining in the basal layers of normal
squamous oesophageal tissue, which has not previously been
reported by others.
HIF-1a expression decreased from NSE to CLO and then
increased with progression to adenocarcinoma. Although HIF-1a
is of interest as a marker of hypoxia, its increase in expression
from CLO to adenocarcinoma might be inflammatory mediated.
Chronic inflammation and reactive oxygen species (ROS)-induced
DNA damage are important in oesophageal tumour carcinogenesis
(Olyaee et al, 1995; Jimenez et al, 2005). Reactive oxygen species
regulate HIF stability and transcriptional activity under hypoxia
and normoxia (Pouyssegur and Mechta-Grigoriou, 2006). Inflam-
mation-mediated COX-2 expression is an early feature of Barrett’s
carcinogenesis (Morris et al, 2001) and, in a gastric cancer model,
the COX-2/PGE2/HIF-1/VEGF pathway was shown to contribute to
tumour angiogenesis (Huang et al, 2005).
As ROS are also involved in the stabilisation of HIF-2a (Guzy
et al, 2005), ROS due to chronic inflammation might also play a
role in the increasing expression of HIF-2 in the Barrett’s sequence.
The high expression of HIF-2a in dysplasia and adenocarcinoma
makes it of interest for further investigation in a case–control
study as a potential predictor of progression to malignancy in
patients with dysplasia. It might have a future role in differentiat-
ing nonspecific (reactive) features that can mimic dysplasia from
true dysplasia or early well-differentiated adenocarcinoma.
Epo was expressed in normal squamous oesophageal tissue and
there was no increase in expression along the progression
sequence. Erythropoietin receptor, however, was expressed more
abundantly and staining increased from normal squamous tissue
to invasive oesophageal cancer. Of interest, both were expressed
earlier in the Barrett’s sequence than either HIF-1a or HIF-2a.
Non-hypoxia stimulation of Epo/Epo-R involves a variety of
factors, including various hormones and cytokines (Hardee et al,
2006). In addition to regulation of red blood cell production, the
pleiotropic effects of Epo/Epo-R signalling include stimulation of
proliferation and angiogenesis (Hardee et al, 2006). Erythropoietin
has been shown to act in the protection of tissue from injury
and can decrease inflammation (Grasso et al, 2004). The early
expression of Epo and its receptor in the Barrett’s sequence is
probably, therefore, related to their role in protection from
inflammation rather than hypoxia response.
There was a reasonably high correlation between the scores of
many of the immunohistochemical markers studied. This is
probably a reflection of the biological similarity of the proteins
studied in terms of their response to inflammation and involve-
ment in the stimulation of angiogenesis and proliferation.
There is interest in using molecular markers to identify patients
with a high risk of developing adenocarcinoma in whom
surveillance endoscopy can be targeted. It is probably unlikely
that a single marker will be sufficient, as there appears to be no
simple evolution of genetic or molecular alterations in disease
progression (Jenkins et al, 2002). Rather there appears to be a
heterogeneous accumulation of genetic and molecular changes in























































CLO IM Dys Adeno
Figure 3 Comparison of the expression of HIF-2a, VEGF, Ki67 and
Epo-R in normal squamous epithelium compared with adjacent columnar-
lined oesophagus (CLO), intestinal metaplasia (IM), dysplasia (Dys) and
adenocarcinoma (Adeno). A total of 40 biopsies were studied.
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s(Jenkins et al, 2002). As the molecular changes are known to be
extremely complex, this is impeding further research. In addition,
this heterogeneity may ultimately be responsible for the poor
response of these tumours to therapy. Given the multiple genetic
alterations, which are implicated in the natural history of
oesophageal adenocarcinoma, a combination of clinical risk
factors and carefully validated biomarkers might improve further
the predictive value of the molecular approach (Bani-Hani et al,
2000; Bani-Hani et al, 2005) and allow targeted surveillance.
HIF-2a, VEGF, Epo-R and Ki67 showed increased expression
with progression along the Barrett’s carcinogenesis sequence. The
late expression of HIF-1a and HIF-2a, key mediators of gene
induction in response to hypoxia, suggests that hypoxia might
not be a key factor driving oesophageal cancer development. As
discussed above, ROS and inflammation are likely to be involved
in the stimulation of many of the proteins studied. The conclusion
from this work, therefore, is that hypoxia is probably not
important in the aetiology of oesophageal cancer. The late
expression of HIF-2a in the Barrett’s sequence and its high
expression in adenocarcinoma suggest that it is worth further
investigation as a marker of disease progression and therapeutic
target.
ACKNOWLEDGEMENTS
We thank David Ryder, Department of Statistics, Christie Hospital
for help with the statistical analysis and Dr Jo Cresswell, Academic
Radiation Oncology, Christie Hospital, Manchester for adminis-
trative support. This work was supported by Cancer Research UK
and the National Translational Research Network of the UK.
REFERENCES
Acs G, Xu X, Chu C, Acs P, Verma A (2004) Prognostic significance of
erythropoietin expression in human endometrial carcinoma. Cancer 100:
2376–2386
Acs G, Zhang PJ, McGrath CM, Acs P, McBroom J, Mohyeldin A, Liu S, Lu
H, Verma A (2003) Hypoxia-inducible erythropoietin signaling in
squamous dysplasia and squamous cell carcinoma of the uterine cervix
and its potential role in cervical carcinogenesis and tumor progression.
Am J Pathol 162: 1789–1806
Acs G, Zhang PJ, Rebbeck TR, Acs P, Verma A (2002) Immunohisto-
chemical expression of erythropoietin and erythropoietin receptor in
breast carcinoma. Cancer 95: 969–981
Auvinen MI, Sihvo EI, Ruohtula T, Salminen JT, Koivistoinen A, Siivola P,
Ronnholm R, Ramo JO, Bergman M, Salo JA (2002) Incipient
angiogenesis in Barrett’s epithelium and lymphangiogenesis in Barrett’s
adenocarcinoma. J Clin Oncol 20: 2971–2979
Bani-Hani K, Martin IG, Hardie LJ, Mapstone N, Briggs JA, Forman D, Wild
CP (2000) Prospective study of cyclin D1 overexpression in Barrett’s
esophagus: association with increased risk of adenocarcinoma. J Natl
Cancer Inst 92: 1316–1321
Bani-Hani KE, Bani-Hani BK, Martin IG (2005) Characteristics of patients
with columnar-lined Barrett’s esophagus and risk factors for progression
to esophageal adenocarcinoma. World J Gastroenterol 11: 6807–6814
Bergman JJ, Tytgat GN (2005) New developments in the endoscopic
surveillance of Barrett’s oesophagus. Gut 54(Suppl 1): i38–i42
Bertheau P, Cazals-Hatem D, Meignin V, de Roquancourt A, Verola O, Lesourd
A, Sene C, Brocheriou C, Janin A (1998) Variability of immunohistochemical
reactivity on stored paraffin slides. JC l i nP a t h o l51: 370–374
Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM,
Abeloff MD, Simons JW, van Diest PJ, van der Wall E (2001) Levels of
hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl
Cancer Inst 93: 309–314
Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA (2002) Surveillance
and survival in Barrett’s adenocarcinomas: a population-based study.
Gastroenterology 122: 633–640
Costa A, Coradini D, Carrassi A, Erdas R, Sardella A, Daidone MG (2001)
Re: Levels of hypoxia-inducible factor-1alpha during breast carcino-
genesis. J Natl Cancer Inst 93: 1175–1177
Couvelard A, Paraf F, Gratio V, Scoazec JY, Henin D, Degott C, Flejou JF
(2000) Angiogenesis in the neoplastic sequence of Barrett’s oesophagus.
Correlation with VEGF expression. J Pathol 192: 14–18
Feith M, Stein HJ, Mueller J, Siewert JR (2004) Malignant degeneration of
Barrett’s esophagus: the role of the Ki-67 proliferation fraction,
expression of E-cadherin and p53. Dis Esophagus 17: 322–327
Feldman L, Wang Y, Rhim JS, Bhattacharya N, Loda M, Sytkowski AJ
(2006) Erythropoietin stimulates growth and STAT5 phosphorylation in
human prostate epithelial and prostate cancer cells. Prostate 66: 135–145
Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL
(1996) Activation of vascular endothelial growth factor gene transcrip-
tion by hypoxia-inducible factor 1. Mol Cell Biol 16: 4604–4613
Grasso G, Sfacteria A, Cerami A, Brines M (2004) Erythropoietin as a tissue-
protective cytokine in brain injury: what do we know and where do we
go? Neuroscientist 10: 93–98
Griffiths EA, Pritchard SA, Valentine HR, Whitchelo N, Bishop PW, Ebert
MP, Price PM, Welch IM, West CM (2007) Hypoxia-inducible factor-
1alpha expression in the gastric carcinogenesis sequence and its
prognostic role in gastric and gastro-oesophageal adenocarcinomas.
Br J Cancer 96: 95–103
Guindi M, Riddell RH (2003) Histology of Barrett’s esophagus and
dysplasia. Gastrointest Endosc Clin N Am 13: 349–368, , viii
Guzy RD, Hoyos B, Robin E, Chen H, Liu L, Mansfield KD, Simon MC,
Hammerling U, Schumacker PT (2005) Mitochondrial complex III is
required for hypoxia-induced ROS production and cellular oxygen
sensing. Cell Metab 1: 401–408
Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, Dewhirst MW
(2006) Erythropoietin biology in cancer. Clin Cancer Res 12: 332–339
Huang SP, Wu MS, Shun CT, Wang HP, Hsieh CY, Kuo ML, Lin JT (2005)
Cyclooxygenase-2 increases hypoxia-inducible factor-1 and vascular
endothelial growth factor to promote angiogenesis in gastric carcinoma.
J Biomed Sci 12: 229–241
Ibrahim NB (2000) ACP. Best Practice No 155. Guidelines for handling
oesophageal biopsies and resection specimens and their reporting. J Clin
Pathol 53: 89–94
Iftikhar SY, Steele RJ, Watson S, James PD, Dilks K, Hardcastle JD (1992)
Assessment of proliferation of squamous, Barrett’s and gastric mucosa in
patients with columnar lined Barrett’s oesophagus. Gut 33: 733–737
Jankowski JA, Wright NA, Meltzer SJ, Triadafilopoulos G, Geboes K,
Casson AG, Kerr D, Young LS (1999) Molecular evolution of the
metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J
Pathol 154: 965–973
Jenkins GJ, Doak SH, Parry JM, D’Souza FR, Griffiths AP, Baxter JN (2002)
Genetic pathways involved in the progression of Barrett’s metaplasia to
adenocarcinoma. Br J Surg 89: 824–837
Jimenez P, Piazuelo E, Sanchez MT, Ortego J, Soteras F, Lanas A (2005) Free
radicals and antioxidant systems in reflux esophagitis and Barrett’s
esophagus. World J Gastroenterol 11: 2697–2703
Keighley MR (2003) Gastrointestinal cancers in Europe. Aliment Pharmacol
Ther 18(Suppl 3): 7–30
Kim SH, Shin YK, Lee KM, Lee JS, Yun JH, Lee SM (2003) An improved
protocol of biotinylated tyramine-based immunohistochemistry
minimizing nonspecific background staining. J Histochem Cytochem
51: 129–132
Kumar SM, Acs G, Fang D, Herlyn M, Elder DE, Xu X (2005)
Functional erythropoietin autocrine loop in melanoma. Am J Pathol
166: 823–830
Lord RV, Park JM, Wickramasinghe K, DeMeester SR, Oberg S, Salonga D,
Singer J, Peters JH, Danenberg KD, Demeester TR, Danenberg PV (2003)
Vascular endothelial growth factor and basic fibroblast growth factor
expression in esophageal adenocarcinoma and Barrett esophagus.
J Thorac Cardiovasc Surg 125: 246–253
McManus DT, Olaru A, Meltzer SJ (2004) Biomarkers of esophageal
adenocarcinoma and Barrett’s esophagus. Cancer Res 64: 1561–1569
Mobius C, Stein HJ, Becker I, Feith M, Theisen J, Gais P, Jutting U, Siewert
JR (2003) The ’angiogenic switch’ in the progression from Barrett’s
metaplasia to esophageal adenocarcinoma. Eur J Surg Oncol 29: 890–894
Hypoxia markers in Barrett’s carcinogenesis
EA Griffiths et al
1382




















sMorris CD, Armstrong GR, Bigley G, Green H, Attwood SE (2001)
Cyclooxygenase-2 expression in the Barrett’s metaplasia-dysplasia-
adenocarcinoma sequence. Am J Gastroenterol 96: 990–996
Odze RD (2006) Diagnosis and grading of dysplasia in Barrett’s
oesophagus. J Clin Pathol 59: 1029–1038
Olapade-Olaopa EO, Ogunbiyi JO, MacKay EH, Muronda CA, Alonge TO,
Danso AP, Moscatello DK, Sandhu DP, Shittu OB, Terry TR, Wong AJ,
Habib FK (2001) Further characterization of storage-related alterations
in immunoreactivity of archival tissue sections and its implications for
collaborative multicenter immunohistochemical studies. Appl Immuno-
histochem Mol Morphol 9: 261–266
Olyaee M, Sontag S, Salman W, Schnell T, Mobarhan S, Eiznhamer D,
Keshavarzian A (1995) Mucosal reactive oxygen species production in
oesophagitis and Barrett’s oesophagus. Gut 37: 168–173
Perneger TV (1998) What’s wrong with Bonferroni adjustments. BMJ 316:
1236–1238
Polkowski W, van Lanschot JJ, Ten Kate FJ, Baak JP, Tytgat GN, Obertop H,
Voorn WJ, Offerhaus GJ (1995) The value of p53 and Ki67 as markers for
tumour progression in the Barrett’s dysplasia-carcinoma sequence. Surg
Oncol 4: 163–171
Pouyssegur J, Mechta-Grigoriou F (2006) Redox regulation of the hypoxia-
inducible factor. Biol Chem 387: 1337–1346
Preston SL, Jankowski JA (2006) Drinking from the fountain of promise:
biomarkers in the surveillance of Barrett’s oesophagus – the glass is half
full!. Gut 55: 1377–1379
Reid BJ, Sanchez CA, Blount PL, Levine DS (1993) Barrett’s esophagus: cell
cycle abnormalities in advancing stages of neoplastic progression.
Gastroenterology 105: 119–129
Schlemper RJ, Riddell RH, Kato Y, Borchard F, Cooper HS,
Dawsey SM, Dixon MF, Fenoglio-Preiser CM, Flejou JF, Geboes K,
Hattori T, Hirota T, Itabashi M, Iwafuchi M, Iwashita A, Kim YI,
Kirchner T, Klimpfinger M, Koike M, Lauwers GY, Lewin KJ,
Oberhuber G, Offner F, Price AB, Rubio CA, Shimizu M, Shimoda T,
Sipponen P, Solcia E, Stolte M, Watanabe H, Yamabe H (2000) The
Vienna classification of gastrointestinal epithelial neoplasia. Gut 47:
251–255
Spechler SJ, Goyal RK (1996) The columnar-lined esophagus,
intestinal metaplasia, and Norman Barrett. Gastroenterology 110:
614–621
Streitz Jr JM, Andrews Jr CW, Ellis Jr FH (1993) Endoscopic surveillance
of Barrett’s esophagus. Does it help? J Thorac Cardiovasc Surg 105:
383–387; discussion 387–388
Yasuda Y, Fujita Y, Matsuo T, Koinuma S, Hara S, Tazaki A, Onozaki M,
Hashimoto M, Musha T, Ogawa K, Fujita H, Nakamura Y, Shiozaki H,
Utsumi H (2003) Erythropoietin regulates tumour growth of human
malignancies. Carcinogenesis 24: 1021–1029
Younes M, Ertan A, Lechago LV, Somoano J, Lechago J (1997) Human
erythrocyte glucose transporter (Glut1) is immunohistochemically
detected as a late event during malignant progression in Barrett’s
metaplasia. Cancer Epidemiol Biomarkers Prev 6: 303–305
Younes M, Lechago J, Chakraborty S, Ostrowski M, Bridges M, Meriano F,
Solcher D, Barroso A, Whitman D, Schwartz J, Johnson C,
Schmulen AC, Verm R, Balsaver A, Carlson N, Ertant A (2000)
Relationship between dysplasia, p53 protein accumulation, DNA ploidy,
and Glut1 overexpression in Barrett metaplasia. Scand J Gastroenterol 35:
131–137
Hypoxia markers in Barrett’s carcinogenesis
EA Griffiths et al
1383
British Journal of Cancer (2007) 96(9), 1377–1383 & 2007 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s